Table 2.
Characteristics of clinical trials, patients and efficacy included in the meta-analysis
| Reference | Cancer | Combinative treatment | Number of patients | Median PFS (months) | HR of PFS [95% CI] | RR | |||
|---|---|---|---|---|---|---|---|---|---|
| Eve. | Cont. | Eve. | Cont. | Eve./Cont. | Eve. | Cont. | |||
| [11] | Postmenopausal hormone-receptor-positive advanced breast cancer | 25mg exemestane/day | 482 | 238 | 6.9 | 2.8 | 0.43 [0.35–0.54] | 9.5% | 0.4% |
| [13] | Advanced neuroendocrine tumors associated with carcinoid syndrome | 30mg octreotide/month | 216 | 213 | 16.4 | 11.3 | 0.77 [0.59–1.00] | 2.3% | 1.9% |
| [14] | Advanced RCC | No | 269 | 135 | 4.0 | 1.9 | 0.30 [0.22–0.40] | 1.0% | 0.0% |
| [12] | Advanced pancreatic neuroendocrine tumor | No | 207 | 203 | 11 | 4.6 | 0.35 [0.27–0.45] | 5.0% | 2.0% |
RCC, renal cell carcinoma; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; RR, response rate; Eve, everolimus; Cont, control.